YP
NVIV

Yellowstone Partners’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History

Yellowstone Partners’s Portfolio NVIV Stock Details NVIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-1
Closed -$72K – 251
2015
Q4 		$72K Buy
+1
New +$149K 0.03% 212

Other funds holding NVIV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WF
Welch & Forbes Boston, Massachusetts $7.73B AUM 14.94% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
ICM
IMS Capital Management Portland, Oregon $217M AUM 18.69% 1-Year Est. Return

Yellowstone Partners's NVIV Position: Q1 2016 in Review

Yellowstone Partners sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q1 2016, closing a stake of 1 share — an estimated $72K sold.

Yellowstone Partners first reported a position in NVIV in Q4 2015 and held it in 1 quarter. The position peaked at $72K in Q4 2015. 46 funds tracked by Wall St. Rank hold NVIV as of Q1 2016.

  • Yellowstone Partners reported no remaining InVivo Therapeutics Holdings Corp position as of Q1 2016 after selling out during the quarter.
  • Yellowstone Partners sold 1 InVivo Therapeutics Holdings Corp share in Q1 2016, an estimated $72K.
  • Yellowstone Partners first reported a position in InVivo Therapeutics Holdings Corp in Q4 2015 and held it in 1 quarter.
  • Yellowstone Partners's InVivo Therapeutics Holdings Corp position peaked at $72K in Q4 2015.
  • 46 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q1 2016.

Based on Yellowstone Partners's 13F filing for Q1 2016, filed 17 Aug 2016.